A Phase 1B Investigator Initiated Study To Evaluate The Preliminary Activity, Safety And Tolerability Of ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers
Latest Information Update: 07 Aug 2025
At a glance
- Drugs Denosumab (Primary) ; ETC 1922159 (Primary) ; Pembrolizumab (Primary) ; Zoledronic acid (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms ETC-159-02
Most Recent Events
- 25 Jul 2025 Status changed from not yet recruiting to recruiting.
- 25 Jul 2024 New trial record